Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

767.85 -7.68 (-0.99%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	596,651
Open	764.15
Bid (Size)	761.00 (80)
Ask (Size)	775.00 (40)
Prev. Close	775.53
Today's Range	761.50 - 772.45
52wk Range	476.49 - 821.11
Shares Outstanding	91,779,465
Dividend Yield	0.49%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm

April 06, 2026

The United States labor market is currently defying traditional economic gravity, showcasing a resilient "low-hire, low-fire" dynamic that has left analysts and investors recalibrating their...

Via MarketMinute

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Performance

YTD	-1.1%	-1.1%
1 Month	-1.8%	-1.8%
3 Month	-5.5%	-5.5%
6 Month	+36.2%	+36.2%
1 Year	+37.9%	+37.9%

More News

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

April 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

April 02, 2026

Via StockStory

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

April 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena ↗

March 30, 2026

Via The Motley Fool

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

Via MarketMinute

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

Via MarketMinute

Is Regeneron a Multimillionaire-Maker Stock? ↗

March 27, 2026

Via The Motley Fool

Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment

March 26, 2026

Via MarketMinute

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

Via Finterra

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

March 25, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

March 24, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

Via The Motley Fool

Is Eli Lilly's Weight Loss Empire in Trouble? ↗

March 13, 2026

Via The Motley Fool

3 Profitable Stocks We Think Twice About

March 13, 2026

Via StockStory

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making ↗

March 12, 2026

Via The Motley Fool

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

March 09, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

Via The Motley Fool

1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

March 05, 2026

Via StockStory

Regeneron Announces Investor Conference Presentation

March 05, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Biotech Giants to Buy in 2026 ↗

March 05, 2026

Via The Motley Fool

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

February 27, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

February 26, 2026

From Society For Science

Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 767.85

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 04/09/26 04:00 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 70.47B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 70B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.